167 related articles for article (PubMed ID: 8886035)
1. [Chemotherapy for pancreatic cancer].
Sakata Y; Takemori H; Suzuki H
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1647-50. PubMed ID: 8886035
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based combination treatment of pancreatic cancer.
Heinemann V
Semin Oncol; 2002 Feb; 29(1 Suppl 3):25-35. PubMed ID: 11894005
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine: progress in the treatment of pancreatic cancer.
Heinemann V
Oncology; 2001; 60(1):8-18. PubMed ID: 11150902
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Kozuch P; Petryk M; Bruckner HW
Hematol Oncol Clin North Am; 2002 Feb; 16(1):123-38. PubMed ID: 12063823
[TBL] [Abstract][Full Text] [Related]
7. [Gemcitabine-based combinations in inoperable pancreatic cancers].
Louvet C; André T; Artru P
Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
[TBL] [Abstract][Full Text] [Related]
8. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Heinemann V
Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
[TBL] [Abstract][Full Text] [Related]
10. Present and future treatment of pancreatic cancer.
Heinemann V
Semin Oncol; 2002 Jun; 29(3 Suppl 9):23-31. PubMed ID: 12094335
[TBL] [Abstract][Full Text] [Related]
11. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel in the management of advanced pancreatic cancer.
Lopes G; Rocha Lima CM
Semin Oncol; 2005 Apr; 32(2 Suppl 4):S10-23. PubMed ID: 16015551
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
16. [Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
Kobayashi A; Yamaguchi M
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1755-9. PubMed ID: 9757202
[TBL] [Abstract][Full Text] [Related]
17. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
18. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
19. [Progress in chemotherapy for advanced gastric cancer].
Xu RH; Teng KY
Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
[TBL] [Abstract][Full Text] [Related]
20. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]